E Galena Biopharma Announces Reduction Of Cardiac Toxicity Study For Neuvax Trial

Shares of Galena Biopharma, Inc. (GALE) closed the day with 11% up, after the company had announced that the independent data monitoring committee  - IDMC  - reduced the monitoring of the cardiac toxicity study for the Neuvax trial known as "PRESENT".

This is important because other breast cancer studies targeting the HER2 expression have seen some safety issues of cardiac toxicity. The fact that the IDMC recommended the reduction of such a study shows the continued safety for Neuvax in these patients with breast cancer. 

The IDMC is a group of physicians that consists of oncologists, cardiologists, and an independent statistician who are all responsible for determining whether a study is safe enough for patients to continue. In addition this group also monitors other areas such as efficacy and recommend whether or not the study should be done to completion. 

Disclosure: None.

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.